NICE has today (4 February 2020) published the outcome of the appeal against its final draft guidance (FAD) on erenumab (also called Aimovig and made by Novartis) for preventing chronic migraine.
An expanded evidence base could allow NICE to address evidence gaps and enhance reviews of the impact of our guidance
More evidence on the clinical and cost effectiveness of esketamine needed
NICE has today, 30 January 2020, published a simple guide to the way we develop our guidance and standards.
Applications close on Wednesday 4 March 2020
Axonics SNS has potential to save the NHS around £6,200 per patient if the device lasts more than six years
Health professionals can consider digital and mobile interventions as a supplement to regular services to support behaviour change in people at risk of developing chronic conditions.
Dame Philippa Russell, Vice-President of Carers UK and Topic Adviser for the NICE guideline on Supporting Adult Carers
Community pharmacy teams have the potential to play a greater role in health promotion and prevention says NICE, in a new draft quality standard.
Larotrectinib (also called Vitrakvi and made by Bayer), a new treatment for a range of cancers, can’t be recommended for use in the NHS because at its current price, it doesn’t have the potential to be cost-effective.
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on the Cancer Drugs Fund (CDF) following its approval by NICE in final guidance published today (15 January 2020).
Doctors can check on their patients remotely using Reveal LINQ monitor
Submit your shared learning entry by 4 March 2020 for a chance to be one of our 20 finalists at this year’s NICE Conference
Paper looks at how histology-independent cancer drugs might be appraised
A new draft NICE guideline published today (20 December 2019) on the rehabilitation of adults with complex psychosis and related mental health conditions says they should have access to rehabilitation services in their local area and the use of out-of-area placements limited.
As a public body, NICE is required to follow civil service principles on communicating during the lead up to the general election.
Chris Bird, Quality Standards Programme Manager, tells us how NICE developed the latest learning disability quality standards
Study will measure public’s preference for different health states
An ovarian cancer treatment, designed to help maintain the effects of chemotherapy, has been approved by NICE for use in the Cancer Drugs Fund (CDF).
Draft guidance published today (3 October 2019) by NICE does not recommend atezolizumab (also called Tecentriq and made by Roche) for treating people with a type of breast cancer called triple A breast cancer that has spread to other parts of the body and who can’t have surgery to remove it.
NICE has said that a new drug for preventing migraine is not a cost effective use of NHS resources, in final draft guidance published today (26 September 2019).
Operations are set to start taking place in the NHS
Regularly monitoring women who are pregnant with twins or triplets, to spot any possible complications, can lead to better outcomes for mothers and their babies, as highlighted in NICE’s impact report.
Deborah Duval, the editor of Kidney Matters magazine, tells us how we can enjoy food even on a restricted renal diet
Consultation on priority areas open to stakeholders until mid October
Higher quality evidence would allow NICE to make recommendations on a range of therapies that could help people with tinnitus.
Heidi Livingstone, senior public involvement adviser within NICE's Public Involvement Programme, reflects on the partnership with CMAC
Recruitment for the 2020 intake is open until 28 October 2019
It is estimated that in the UK there are around 30 to 50 children living with the condition
Providing support after a suspected suicide can reduce this risk, especially when tailored to the person’s needs.
It's estimated that 86 people would be eligible for treatment with voretigene neparvovec in England